<DOC>
	<DOCNO>NCT00324324</DOCNO>
	<brief_summary>RATIONALE : A donor stem cell transplant low body 's immune system , make difficult fight infection . Giving antibiotic , moxifloxacin , may help prevent bacterial infection patient recently undergone donor stem cell transplant . It yet know whether moxifloxacin effective placebo prevent bacterial infection patient recently undergone donor stem cell transplant . PURPOSE : This randomized phase III trial study moxifloxacin see well work compare placebo prevent bacterial infection patient recently undergone donor stem cell transplant .</brief_summary>
	<brief_title>Moxifloxacin Preventing Bacterial Infections Patients Who Have Undergone Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess safety tolerability give prophylactic moxifloxacin hydrochloride post-engraftment phase patient undergone allogeneic stem cell transplantation . ( Pilot study ) - Compare efficacy , term reduce incidence clinically microbiologically document bacterial infection , patient undergo allogeneic stem cell transplantation treat prophylactic moxifloxacin hydrochloride v placebo post-engraftment phase . ( Phase III ) Secondary - Determine incidence clinically microbiologically document bacterial infection patient . ( Pilot study ) - Assess impact moxifloxacin hydrochloride incidence bacteremia patient . ( Phase III ) - Compare percentage time systemic antibiotic day hospitalize patient treated regimen . ( Phase III ) - Compare incidence veno-occlusive disease liver patient treat regimen . ( Phase III ) - Compare incidence severity graft-versus-host disease patient treat regimen . ( Phase III ) - Compare infection-related mortality overall mortality patient treat regimen . OUTLINE : This pilot study follow randomize , double-blind , placebo-controlled , multicenter phase III study . Patients stratify accord gender race ( white vs. non-white ) . The first 20 patient assign pilot study . Patients assign pilot study receive oral moxifloxacin hydrochloride daily begin neutrophil recovery ( ANC &gt; 1,500/mm³ ) allogeneic stem cell transplantation ( ASCT ) continue day 100 post-transplantation absence disease progression unacceptable toxicity . Subsequent patient randomize 1 2 treatment arm . - Arm I : Patients receive oral moxifloxacin hydrochloride daily begin neutrophil recovery ( ANC &gt; 1,500/mm³ ) ASCT continue day 100 post-transplantation . - Arm II : Patients receive oral placebo daily begin neutrophil recovery ( ANC &gt; 1,500/mm³ ) ASCT continue day 100 post-transplantation . In arm , treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow day 120 post-transplantation . PROJECTED ACCRUAL : A total 240 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must planning undergo complete allogeneic stem cell transplantation ( ASCT ) Must undergo nonmyeloablative ASCT Must require antibiotic prophylaxis bacterial pathogen postengraftment phase per ASCT protocol No know colonization antimicrobialresistant organism normally sensitive quinolones know increase infection incidence ( i.e. , ciprofloxacinresistant Pseudomonas allow ; vancomycinresistant Enterococcus methicillinresistant Staphylococcus aureus allow ) PATIENT CHARACTERISTICS : Life expectancy ≥ 100 day Not pregnant nursing Fertile patient must use effective contraception Negative pregnancy test No know hypersensitivity fluoroquinolones No prolonged QTc interval EKG ( i.e. , QTc &gt; 440 millisecond ) No uncontrolled hypokalemia PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent class IA ( e.g. , quinidine procainamide ) class III ( e.g. , amiodarone sotalol ) antiarrhythmics No concurrent intravenous antibiotic preenrollment infection except vancomycin , linezolid , dalfopristin , quinupristin ( Synercid® )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>infection</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL negative</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>